Respiratory Syncytial Virus (RSV), a common virus causing mild cold-like symptoms in most people, can lead to severe lower respiratory tract infections, hospitalizations, and even deaths particularly in infants and older adults. The RSV season, which typically begins in the fall and peaks in the winter, is a significant health concern. However, the advent of RSV passive immunization, a preventive strategy, offers a promising solution to this alarming health issue.
Table of Contents
The Effectiveness of RSV Passive Immunization
Passive immunization involves providing antibodies to a person to help prevent or fight off diseases. For RSV, passive immunization has been found to be particularly effective in protecting infants. A study published in Eurosurveillance Rapid Communication on January 25, 2024, concluded that Beyfortus™(Nirsevimab) was about 69% effective at preventing pediatric respiratory syncytial virus (RSV) hospitalizations in infants. The study provided early real-world evidence of nirsevimab immunization protecting infants from severe RSV disease in Luxembourg.
Beyfortus Nirsevimab: A Significant Development in Infant Health
The introduction of Beyfortus Nirsevimab in the U.S. is a significant development in the field of infant health. This RSV antibody product can help prevent severe symptoms of RSV disease in certain infants and young children. In 2023, there were 241 children under five years of age hospitalized with a laboratory-confirmed RSV infection, compared with 389 cases in 2022, representing decreases of 38% in cases under five years of age and 69% in cases of infants under six months old.
RSV Vaccines for Adults
While the focus is on protecting infants, it is important to note that RSV also affects older adults. The U.S. government has approved the first two RSV vaccines for people 60 years and older to prevent lower respiratory tract disease caused by RSV. These vaccines include RSVPreF3 Arexvy GSK and RSVpreF Abrysvo Pfizer. There are recent filings indicating that adults 50 years and older may have access to these vaccines in time for the next RSV season. This is a step forward in reducing the burden of RSV in the older population.
Role of Pharmacists in RSV Vaccination
Pharmacists play a crucial role in providing education and administering RSV vaccines. By recommending RSV vaccination for adults aged 60 years and older and by providing necessary information about RSV vaccines, monoclonal antibodies, and preventive strategies for RSV hospitalizations in pediatric patients, pharmacists can help increase vaccination coverage.
The development and availability of RSV passive immunization, especially Beyfortus Nirsevimab, is indeed a positive development in the field of infant health. It offers a promising solution for preventing RSV infections in the vulnerable population. The study’s findings have the potential to impact healthcare strategies for pregnant women and infants, making RSV prevention more effective and accessible.
